A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Conditions: Non-small Cell Lung Cancer; Breast Cancer; Gastric Cancer; Renal Cell Carcinoma; Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Cholangiocarcinoma; Bladder Urothelial Carcinoma; MSI-H Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Head and Neck Cancer; Other Solid Tumors
Intervention: Drug: CDX-527
Sponsor: Celldex Therapeutics
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.